Missionirnewsbreaks Heartbeam Inc. (NASDAQ: BEAT) Reports Positive ALIGN-ACS Pilot Study Results For Heart Attack Assessment Technology

(MENAFN- Investor Brand Network) HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac monitoring and detection, announced positive results from its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack assessment. The findings were presented at the Transcatheter Cardiovascular Therapeutics (“TCT”) 2026 conference in San Diego. The study enrolled 132 adults and compared HeartBeam's portable, cable-free electrocardiogram (“ECG”) technology with standard 12-lead ECGs in assessing acute coronary syndrome (“ACS”). HeartBeam demonstrated higher specificity than conventional ECGs (81.8% versus 71.4%) and comparable sensitivity (60.2% versus 63.0%). For ST-elevation myocardial infarction (“STEMI”), sensitivity was 82.9% for HeartBeam compared with 83.8% for standard ECGs. All participants successfully recorded their own ECGs under clinical supervision without prior training.

The study also found greater consistency among cardiologists interpreting HeartBeam recordings compared with standard ECGs, supporting the technology's potential for remote cardiac assessment. HeartBeam plans to use the findings to inform a U.S. pivotal study expected to begin in the first quarter of 2027, with the goal of supporting a future Food and Drug Administration (“FDA”) submission to expand the system's indication beyond arrhythmia assessment to include heart attack assessment. Although HeartBeam's heart attack assessment technology has received FDA Breakthrough Device Designation, the application remains investigational and is not currently FDA-cleared for heart attack assessment.

To view the full press release, visit

About HeartBeam, Inc.

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025(1). The Company holds over 20 issued patents related to technology enablement.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company's newsroom at

(1) Cleared Indications for Use

The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company's Cleared Indications for Use at for details on the intended use of its technology.

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio IBN: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: imer, class="wp-block-paragraph">MissionIR
Austin, Texas

512.354.7000 Office
href="/cdn-cgi/l/email-protection#9bdefff2eff4e9dbd6f2e8e8f2f4f5d2c9b5f8f4f6" target="_blank" rel="noreferrer noopener">[email protected]

MissionIR is powered by IBN

MENAFN02112026000224011066ID1111904324